CENTESSA PHARMACEUTICALS Market Cap ($5.35 Billion)
Market Cap & Net Worth: CENTESSA PHARMACEUTICALS (260)
CENTESSA PHARMACEUTICALS market cap. CENTESSA PHARMACEUTICALS (F:260) has a market capitalization of $5.35 Billion (€4.58 Billion) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #3313 globally and #634 in its home market, demonstrating a 2.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CENTESSA PHARMACEUTICALS's stock price €34.60 by its total outstanding shares 154731309 (154.73 Million). Also see CENTESSA PHARMACEUTICALS operating cash flow efficiency for how efficiently the company converts equity into cash flow.
CENTESSA PHARMACEUTICALS Market Cap History (2021–2026)
CENTESSA PHARMACEUTICALS market cap history from 2021 to 2026. Data shows growth from $1.78 Billion to $6.26 Billion (14.05% CAGR). Check today's stock price for CENTESSA PHARMACEUTICALS for real-time trading data and today's change.
CENTESSA PHARMACEUTICALS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CENTESSA PHARMACEUTICALS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 260 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
180.90x
CENTESSA PHARMACEUTICALS's market cap is 180.90 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.26 Billion | $6.85 Million | -$151.09 Million | 183.46x | N/A |
| 2025 | $2.71 Billion | $15.00 Million | -$197.53 Million | 180.90x | N/A |
Competitor Companies of 260 by Market Capitalization
Companies near CENTESSA PHARMACEUTICALS in the global market cap rankings as of November 4, 2026. Also see 260 total assets for a full breakdown of the balance sheet.
Key companies related to CENTESSA PHARMACEUTICALS by market ranking:
- CICT Mobile Communication Technology Co. Ltd. A (SHG:688387): Ranked #3304 globally with a market cap of $5.38 Billion USD ( CN¥36.75 Billion CNY).
- Oberbank AG (VI:OBS): Ranked #3305 globally with a market cap of $5.38 Billion USD ( €4.60 Billion EUR).
- Portland General Electric Co (NYSE:POR): Ranked #3314 globally with a market cap of $5.35 Billion USD.
- SBM Offshore N.V. (AS:SBMO): Ranked #3315 globally with a market cap of $5.34 Billion USD ( €4.57 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #3304 | CICT Mobile Communication Technology Co. Ltd. A | SHG:688387 | $5.38 Billion | CN¥10.75 |
| #3305 | Oberbank AG | VI:OBS | $5.38 Billion | €83.60 |
| #3314 | Portland General Electric Co | NYSE:POR | $5.35 Billion | $45.52 |
| #3315 | SBM Offshore N.V. | AS:SBMO | $5.34 Billion | €34.30 |
Market Capitalization of CENTESSA PHARMACEUTICALS (2021–2026)
Market capitalization of CENTESSA PHARMACEUTICALS from 2021 to today. Between 2021 and today, CENTESSA PHARMACEUTICALS's market cap moved from $1.78 Billion to $ 6.26 Billion, with a yearly change of 14.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €6.26 Billion | +130.67% |
| 2025 | €2.71 Billion | -3.85% |
| 2024 | €2.82 Billion | +124.46% |
| 2023 | €1.26 Billion | +139.66% |
| 2022 | €524.60 Million | -70.56% |
| 2021 | €1.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of CENTESSA PHARMACEUTICALS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.35 Billion USD |
| MoneyControl | $5.35 Billion USD |
| MarketWatch | $5.35 Billion USD |
| marketcap.company | $5.35 Billion USD |
| Reuters | $5.35 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hyperso… Read more